Authors
Latest:
Is circulating heat shock protein 60 a marker for susceptibility to cardiovascular disease in patients with diabetes?The vital cell stress protein, heat shock protein (Hsp)60, has recently been found in the circulation of healthy subjects over an extremely large concentration range. We performed an analysis of subjects with diabetes to determine whether Hsp60 is associated with biochemical markers of cardiovascular disease. Results showed that high circulating levels of Hsp60 are associated with clinically manifest cardiovascular disease. Hsp60 has cytokine-like actions, which may be responsible for this association.
Latest:
First Annual NCONN Conference a SuccessHistory was made on October 10th, when the National Coalition of Oncology Nurse Navigators (NCONN) held its first annual conference, Changing the Face of Cancer Care,which brought together nurses, social workers, and health care professionals from all over the United States and two Canadian provinces.
Latest:
A Real Life Saver: Technology Plays a Leading Role in the Fight against Hospital-acquired InfectionsHospitals are increasingly using patient safety screening technology in the fight against hospital-acquired infections that kill thousands of patients and drive up the cost of care.
Latest:
Acute coronary syndromes and women: A new eraWomen with acute coronary syndromes continue to be undertreated with pharmacologic therapy and invasive procedures, despite the fact that they receive the same benefits from therapy as men. Although the older age at diagnosis for women adds complexity to clinical decision making, studies show that an aggressive medical or interventional approach to acute coronary syndromes is often warranted and should be based on patient size, comorbidity, and renal function.
Latest:
A weighty problemIf only we could do for diabetes what we have done in the past decade for hyperlipidemia.
Latest:
The SORT OUT II trial: Updated summary with a special focus on stent thrombosis and discontinuation of dual antiplatelet therapy after 1 yearThe SORT OUT II trial showed that the first generation of drug-eluting stents, Cypher® and Taxus®, exhibit similar efficacy and safety when used for percutaneous coronary intervention in everyday practice, including in a high proportion of off-label situations.
Latest:
Don't Rule Out Strongyloides stercoralis Infection Among AllergiesStrongyloides undergo a complex life cycle within humans, and may result in chronic infections that last for several decades even in individuals that have not recently traveled to endemic areas.
Latest:
Alcohol consumption in men with hypertensionWe assessed the association between the incidence of coronary heart disease and alcohol consumption among hypertensive men enrolled in the Health "Professionals" Follow-Up Study. Moderate alcohol consumption (1 to 2 drinks per day) was associated with a lower risk of myocardial infarction, as in the general population, but was not associated with the risks of stroke, total mortality, or mortality from cardiovascular causes. These results show that men with hypertension who drink moderately may not need to change their drinking habits.
Latest:
Discussing Shire's Rare Disease Pipeline with Hartmann Wellhoefer, M.D.Hartmann Wellhoefer, M.D., head of medical affairs at Shire, sits down with RDR at the 14th Annual WORLDSymposium to discuss the company's recent data for lysosomal storage diseases.
Latest:
Researching MPS Therapies with Dr. Patricia Dickson of LA BioMedPatricia Dickson, M.D., discusses similarities between variations of MPS and the both the benefits and challenges of being a researcher in the rare disease community.
Latest:
Freezing in Atrial Fibrillation Ablation: Not So Fast You All…Results from the STOP-AF trial was presented at the recent American College of Cardiology annual conference, and it sure has generated much excitement about atrial fibrillation (AF) ablation. This is a good thing.
Latest:
Early statin therapy in acute coronary syndromePatients who survive an acute coronary syndrome are at much higher risk of a recurrent event within the following month than patients with stable coronary syndromes. Statin therapy lowers the risk of recurrent events for many years but also reduces the risk of another event within the weeks to months following the initial acute coronary syndrome. The mechanisms that contribute to this benefit are likely related to improved endothelial function, decreased vascular inflammation, and reduced prothrombotic factors. Observation studies show an early reduction in mortality with statin therapy started before discharge from the hospital after an acute coronary syndrome.
Latest:
News Reports: June 2007The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women by Prachi Patel-Predd 4) Researchers Develop Pancreatic Cancer Risk Model by Prachi Patel-Predd 5) Beyond BCG: New Bladder Cancer Treatments Offer Hope of Tailored, More Effective Therapies by Diane West 6) Doctor���¢�¯�¿�½�¯�¿�½s Own Brush With Bladder Cancer Gives Him Unique Insight to Patients���¢�¯�¿�½�¯�¿�½ Challenges by Diane West
Latest:
Antithrombotic Therapy in Patients with Atrial Fibrillation and Chronic Kidney DiseaseThe presence of chronic kidney disease (CKD) in patients with atrial fibrillation increases the risk of stroke and thromboembolism (TE) as well as the risk of bleeding, thus complicating their treatment. In this context, it has been suggested that CKD should be included in the CHA2DS2-VASc (Congestive heart failure; Hypertension; Age ≥75 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular disease; Age 65 to 74 years; Sex category) score.
